Literature DB >> 12675717

Factors that influence platelet recovery after transfusion: resolving donor quality from ABO compatibility.

Teresa M Jiménez1, Sachin B Patel, Alvaro A Pineda, Ayalew Tefferi, Whyte G Owen.   

Abstract

BACKGROUND: A system was established to examine the extent to which the apheresis donor determines platelet recovery after transfusion, to measure the impact of ABO identity, and to predict outcome by evaluating the donor. STUDY DESIGN AND METHODS: The percentage of platelet recovery was measured after prophylactic transfusion of apheresis units divided from single donors to paired recipients with uncomplicated thrombocytopenia secondary to leukemia chemotherapy. Platelet microaggregation induced by citrate was measured at the time of apheresis.
RESULTS: Platelet recoveries in paired recipients correlated strongly when both transfusions were ABO- identical. When one recipient was ABO-identical and the other was ABO-nonidentical, nonidentical transfusions yielded one-third the recovery of ABO-identical transfusions. In ABO-identical transfusions, platelet recovery in donors having microaggregates in the before-apheresis ACD sample was one-third that in donors without microaggregates. This difference was observed at 1 and 24 hours. Expression of P-selectin in the apheresis units at the time of transfusion correlated well with ACD microaggregates in the before-apheresis sample.
CONCLUSION: When transfusions of platelets are ABO-identical, donor quality dominates recovery in circulation. Donor quality is predicted by a rapid and simple assay of citrate-induced microaggregation performed at the time of apheresis. When donor quality is factored out, ABO identity prevails.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12675717     DOI: 10.1046/j.1537-2995.2003.00326.x

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.157


  4 in total

1.  Efficacy and Adverse Events of Platelet Transfusion Product-Specific Differences.

Authors:  Peter Hellstern
Journal:  Transfus Med Hemother       Date:  2008-03-17       Impact factor: 3.747

2.  Providing ABO-identical platelets and cryoprecipitate to (almost) all patients: approach, logistics, and associated decreases in transfusion reaction and red blood cell alloimmunization incidence.

Authors:  Kelly F Henrichs; Nedda Howk; Debra S Masel; Mark Thayer; Majed A Refaai; Scott A Kirkley; Joanna M Heal; Neil Blumberg
Journal:  Transfusion       Date:  2011-09-02       Impact factor: 3.157

3.  Longitudinal effects of menopausal hormone treatments on platelet characteristics and cell-derived microvesicles.

Authors:  Virginia M Miller; Brian D Lahr; Kent R Bailey; John A Heit; S Mitchell Harman; Muthuvel Jayachandran
Journal:  Platelets       Date:  2015-04-09       Impact factor: 3.862

4.  Platelet responses to agonists in a cohort of highly characterised platelet donors are consistent over time.

Authors:  S F Garner; A Furnell; B C Kahan; C I Jones; A Attwood; P Harrison; A M Kelly; A H Goodall; R Cardigan; W H Ouwehand
Journal:  Vox Sang       Date:  2016-12-21       Impact factor: 2.144

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.